Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 3;12:811794. doi: 10.3389/fonc.2022.811794

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Chen, Hui, Ma, Nong, Han, Jing, Lee, Xu, Fu, Chang, Hsue and Kong

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Locoregional recurrence-free survival (LRRFS) and disease-free survival (DFS) and molecular subtypes in 247 patients with locally advanced N2-3 breast cancer. There were no significant differences of 4-year cumulative incidence of LRRFS between hypofractionated radiotherapy (HFRT) and conventional fractionated radiotherapy (CFRT) group with HR+/HER2- (A), HER2+ (B) and triple negative breast cancer (TNBC) (C). DFS between HFRT and CFRT group was similar in N2-3 patients with HR+/HER2- (D) and HER2+ (E) breast cancer with no significant difference (ps > 0.05), while N2-3 patients with TNBC had numerically lower DFS in HFRT group than in CFRT group (76.2% and 100% respectively, F).